Opioid Prescribing: Safe Practice, Changing Lives (2 Credits)
- Registration Closed
The CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives course addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. ASAM's course also provides an additional unit addressing the common and complex overlap between opioid use and opioid addiction.
Learners will be able to:
- Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy, as well as possible misuse.
- Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques, as well as appropriate discontinuation strategies.
- Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
- Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
- Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.
.jpg "Speaker image")
Edwin Salsitz
MD, DFASAM
Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified in Addiction Medicine by the American Board of Preventive Medicine, as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.
Dr. Salsitz is a course director for ASAM sponsored Buprenorphine and REMS Opioid trainings, and is a lead mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee.
Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.
Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.
No Relevant Financial Disclosures
CME Information and Disclosure Listing
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Addiction Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 2 AMA PRA Category 1 Credits™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
|
Name |
Nature of Relevant Financial Relationship |
||
|
Commercial Interest |
What was received? |
For what role? |
|
|
Adam J. Gordon, MD, MPH, FACP, DFASAM |
None |
||
|
Catherine Friedman, MD |
None |
||
| Noel Ilogu, MD, MRCP | None | ||
|
Herbert Malinoff, MD, FACP, DFASAM |
None |
||
|
Edwin A. Salsitz, MD, DFASAM |
None |
||
|
John Tanner, DO, DFASAM |
Reckitt Astra Zeneca Pfizer Alkermes |
Honorarium Honorarium Honorarium Honorarium |
Speaker Speaker Speaker Speaker |
Program Planning Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Herbert Malinoff, MD, FACP, DFASAM | None | ||
Yngvild Olsen, MD, MPH | None | ||
Theodore Parran, MD |
None
| ||
Edwin Salsitz, MD, DFASAM | None | ||
R. Corey Waller, MD, MS, FACEP |
None
| ||
Course Faculty
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Edwin Salsitz, MD, DFASAM | None | ||
ASAM CME Committee Reviewers
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Jacob Bobrowski, MD, FAAFP | None | ||
Anthony H. Dekker, DO, DFASAM | None | ||
Acknowledgement
Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.
RPC Commercial Support Disclosure Statement
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.
This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.
Key:
Complete
Next
Failed
Available
Locked